New hope for Hard-to-Treat lymphoma: safer combo therapy under study

NCT ID NCT04161248

First seen Feb 02, 2026 · Last updated Apr 28, 2026 · Updated 13 times

Summary

This study is for people with aggressive B-cell lymphoma that has come back or not responded to treatment. Researchers are testing a new drug added to standard chemotherapy to find the highest dose that is safe and tolerable. The goal is to control the disease and improve outcomes, not to cure it, as ongoing management may still be needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA, B-CELL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • BCCA - Vancouver

    RECRUITING

    Vancouver, British Columbia, V5Z 4E6, Canada

    Contact Phone: •••-•••-••••

  • Kingston Health Sciences Centre

    RECRUITING

    Kingston, Ontario, K7L 2V7, Canada

    Contact Phone: •••-•••-••••

  • The Jewish General Hospital

    RECRUITING

    Montreal, Quebec, H3T 1E2, Canada

    Contact Phone: •••-•••-••••

  • University Health Network

    RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.